Literature DB >> 32768438

Heritable genetic background alters survival and phenotype of Mll-AF9-induced leukemias.

Kira Young1, Matthew A Loberg1, Elizabeth Eudy1, Logan S Schwartz1, Kristina D Mujica1, Jennifer J Trowbridge2.   

Abstract

The MLL-AF9 fusion protein occurring as a result of t(9;11) translocation gives rise to pediatric and adult acute leukemias of distinct lineages, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and mixed-phenotype acute leukemia (MPAL). The mechanisms underlying how this same fusion protein results in diverse leukemia phenotypes among different individuals are not well understood. Given emerging evidence from genome-wide association studies that genetic risk factors contribute to MLL-rearranged leukemogenesis, here we tested the impact of genetic background on survival and phenotype of a well-characterized Mll-AF9 knockin mouse model. We crossed this model with five distinct inbred strains (129, A/J, C57BL/6, NOD, CAST) and tested their F1 hybrid progeny for dominant genetic effects on Mll-AF9 phenotypes. We discovered that genetic background altered peripheral blood composition, with Mll-AF9 CAST F1 having a significantly increased B-lymphocyte frequency, while the remainder of the strains exhibited myeloid-biased hematopoiesis, similar to the parental line. Genetic background also had an impact on overall survival, with Mll-AF9 A/J F1 and Mll-AF9 129 F1 having significantly shorter survival and Mll-AF9 CAST F1 having longer survival, compared with the parental line. Furthermore, we observed a range of hematologic malignancies, with Mll-AF9 A/J F1, Mll-AF9 129 F1, and Mll-AF9 B6 F1 developing exclusively myeloid cell malignancies (myeloproliferative disorder [MPD] and AML), whereas a subset of Mll-AF9 NOD F1 developed MPAL and Mll-AF9 CAST F1 developed ALL. This study provides a novel in vivo experimental model in which to evaluate the underlying mechanisms by which MLL-AF9 results in diverse leukemia phenotypes and provides definitive experimental evidence that genetic risk factors contribute to survival and phenotype of MLL-rearranged leukemogenesis.
Copyright © 2020 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32768438      PMCID: PMC7508790          DOI: 10.1016/j.exphem.2020.07.012

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  24 in total

Review 1.  Targeting epigenetic programs in MLL-rearranged leukemias.

Authors:  Kathrin M Bernt; Scott A Armstrong
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis.

Authors:  C L Dobson; A J Warren; R Pannell; A Forster; I Lavenir; J Corral; A J Smith; T H Rabbitts
Journal:  EMBO J       Date:  1999-07-01       Impact factor: 11.598

3.  High-resolution genetic mapping using the Mouse Diversity outbred population.

Authors:  Karen L Svenson; Daniel M Gatti; William Valdar; Catherine E Welsh; Riyan Cheng; Elissa J Chesler; Abraham A Palmer; Leonard McMillan; Gary A Churchill
Journal:  Genetics       Date:  2012-02       Impact factor: 4.562

4.  The Diversity Outbred mouse population.

Authors:  Gary A Churchill; Daniel M Gatti; Steven C Munger; Karen L Svenson
Journal:  Mamm Genome       Date:  2012-08-15       Impact factor: 2.957

5.  Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.

Authors:  Weili Chen; Ashish R Kumar; Wendy A Hudson; Quanzhi Li; Baolin Wu; Rodney A Staggs; Erik A Lund; Thien N Sam; John H Kersey
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

6.  Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.

Authors:  Junping Wei; Mark Wunderlich; Catherine Fox; Sara Alvarez; Juan C Cigudosa; Jamie S Wilhelm; Yi Zheng; Jose A Cancelas; Yi Gu; Michael Jansen; Jorge F Dimartino; James C Mulloy
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

7.  The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics.

Authors:  Adam Roberts; Fernando Pardo-Manuel de Villena; Wei Wang; Leonard McMillan; David W Threadgill
Journal:  Mamm Genome       Date:  2007-08-03       Impact factor: 2.957

Review 8.  Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions.

Authors:  Anthony K N Chan; Chun-Wei Chen
Journal:  Front Cell Dev Biol       Date:  2019-05-15

9.  The developmental stage of the hematopoietic niche regulates lineage in MLL-rearranged leukemia.

Authors:  R Grant Rowe; Edroaldo Lummertz da Rocha; Patricia Sousa; Pavlos Missios; Michael Morse; William Marion; Alena Yermalovich; Jessica Barragan; Ronald Mathieu; Deepak Kumar Jha; Mark D Fleming; Trista E North; George Q Daley
Journal:  J Exp Med       Date:  2019-02-06       Impact factor: 14.307

10.  SWR/J mice are susceptible to alkylator-induced myeloid leukemia.

Authors:  M R Janke; J D Baty; T A Graubert
Journal:  Blood Cancer J       Date:  2013-11-15       Impact factor: 11.037

View more
  2 in total

1.  Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.

Authors:  Lan Zhang; Xingnong Ye; Shuna Luo; Xiaofei Xu; Shengjie Wang; Keyi Jin; Yan Zheng; Xiaoqiong Zhu; Dan Chen; Jie Jin; Jian Huang
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-22       Impact factor: 4.553

Review 2.  The Genome in a Three-Dimensional Context: Deciphering the Contribution of Noncoding Mutations at Enhancers to Blood Cancer.

Authors:  Llorenç Rovirosa; Alberto Ramos-Morales; Biola M Javierre
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.